Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Bioorganic & Medicinal Chemistry Letters|January 1, 2026
Discovery of novel 4-aminobenzamide derivatives as small molecule CBX2 inhibitorsYuichiro Kawamoto, Shohei Takase, Kumar Ashutosh, et al.
Bioscience, Biotechnology, and Biochemistry|February 22, 2023
Identification of a derivative of the alkaloid emetine as an inhibitor of the YAP-TEAD interaction and its potential as an anticancer agentSaaya Sekine, Shohei Takase, Runa Hayase, et al.
Cancer Discovery|August 31, 2021
Mitochondrial Fragmentation Triggers Ineffective Hematopoiesis in Myelodysplastic SyndromesYasushige Aoyagi, Yoshihiro Hayashi, Yuka Harada, et al.
Chemmedchem|June 9, 2018
Development of Novel Inhibitors for Histone Methyltransferase SET7/9 based on CyproheptadineTomoya Hirano, Takashi Fujiwara, Hideaki Niwa, et al.
European Journal of Medicinal Chemistry|March 14, 2024
Ligand-based design and synthesis of new trityl histamine and trityl cysteamine derivatives as SIRT2 inhibitors for cancer therapyMostafa M Badran, Samar H Abbas, Hiroshi Tateishi, et al.
The Journal of Biological Chemistry|May 7, 2020
The evolutionarily conserved deubiquitinase UBH1/UCH-L1 augments DAF7/TGF-β signaling, inhibits dauer larva formation, and enhances lung tumorigenesisAsami Nagata, Fumiko Itoh, Ayaka Sasho, et al.
Biochemical and Biophysical Research Communications|May 2, 2025
Identification of substituted acetanilide compounds as small molecule CBX2 inhibitors via in silico screeningShohei Takase, Ashutosh Kumar, Sho Yokoyama, et al.
The Journal of Biological Chemistry|May 22, 2023
LPGAT1/LPLAT7 regulates acyl chain profiles at the sn-1 position of phospholipids in murine skeletal musclesTomoki Sato, Shuhei Umebayashi, Nanami Senoo, et al.
Blood Advances|April 5, 2019
NUP98-HBO1-fusion generates phenotypically and genetically relevant chronic myelomonocytic leukemia pathogenesisYoshihiro Hayashi, Yuka Harada, Yuki Kagiyama, et al.
Bioorganic & Medicinal Chemistry Letters|June 24, 2024
Structure-based development of novel substrate-type G9a inhibitors as epigenetic modulators for sickle cell disease treatmentYosuke Nishigaya, Shohei Takase, Tatsunobu Sumiya, et al.
Pageof 3